NCT04425291已完成3 期
A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,680
- 试验地点
- 1
- 主要终点
- Percentage of participants 20 to 45 Years of Age that achieve the neutralizing antibody serostatus cutoffs for seroconversion to HPV Types 6, 11, 16 and 18 at least 1 month post Dose 3.
研究概览
简要总结
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Chinese women aged 20-45 who can provide legal identification;
- •The subject agreed to participate in the study, and voluntarily signs the informed consent;
- •Subjects are able to understand the study procedures and participate in follow-up according to the study requirements;
- •When the subjects were enrolled, the urine pregnancy test was negative, they were not in the lactation period and had no family planning within 7 months after enrollment.2 weeks before included in the study, effective contraceptive measures has been adopted and agreed to in the first seven months after the study (vaccinations after 1 months ago) continue to adopt effective contraceptive measures (effective contraceptive measures including the pill or condoms, etc );
排除标准
- •Have been vaccinated with commercially available HPV vaccine in the past or planned to be vaccinated with commercially available HPV vaccine during the study period;Or have participated in a clinical trial of the HPV vaccine;
- •Has a history of cervical diseases, such as cervical screening showing abnormal results including CIN or a history of hysterectomy (vaginal or total abdominal hysterectomy) or pelvic radiation therapy. Has a history of genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, vulvar cancer, vaginal cancer and anal cancer, etc.) or has a previous sexual history (including syphilis, gonorrhea, chancre, venereal lymphatic granuloma, granuloma inguinal);
- •A history of severe allergies requiring medical intervention, such as anaphylactic shock, anaphylactic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc;
- •Have an acute illness or an acute episode of a chronic illness within 3 days prior to vaccination or the use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.);
- •Subjects received inactivated or recombinant vaccines within 14 days prior to study enrollment, or attenuated live vaccines within 28 days prior to study enrollment;
- •Subjects present with immune impairment or have been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases. Long-term immunosuppressive therapy, e.g., long-term (more than 2 weeks) treatment with glucocorticoids (e.g., prednisone or similar drugs);
- •Has been diagnosed with a severe congenital malformation or chronic disease such as Down syndrome, heart disease, liver disease, kidney disease, diabetes, etc., which may interfere with the conduct or completion of the study;
- •Subject receives any immunoglobulin or blood product within 3 months prior to the first dose of vaccination;
- •Participating in other (drug or vaccine) clinical trials prior to enrollment or planning to participate during the study;
- •Has been diagnosed with an infectious disease, such as tuberculosis, viral hepatitis and/or HIV infection;
- •A history or family history of convulsions, epilepsy, encephalopathy and mental illness;
- •Have contraindications to intramuscular injection, such as having been diagnosed with thrombocytopenia, any coagulation disorder or receiving anticoagulant therapy;
- •Absence of a spleen, functional absence of a spleen, and absence or removal of a spleen in any case;
- •Body temperature ≥37.3℃ (underarm body temperature);
- •Subjects may be unable to comply with the study procedure, comply with the agreement, or plan to permanently relocate from the region prior to completion of the study, or may be permanently absent from the region during the scheduled visit;
- •In the opinion of the investigators, the subjects had any other factors that made them unsuitable to participate in the clinical trial.
结局指标
主要结局
Percentage of participants 20 to 45 Years of Age that achieve the neutralizing antibody serostatus cutoffs for seroconversion to HPV Types 6, 11, 16 and 18 at least 1 month post Dose 3.
时间窗: 1 month post vaccination 3 (Month 7)
次要结局
- The neutralizing antibody GMTs for HPV Types 6, 11, 16 and 18 in participants 20 to 45 Years of Age at least 1 month post Dose 3.(1 month post vaccination 3 (Month 7))
- Percentage of participants that achieve neutralizing antibody quadruple growth ratefor HPV Types 6, 11, 16 and 18 in participants 20 to 45 Years of Age at least 1 month post Dose 3.(1 month post vaccination 3 (Month 7))
- Percentage of participants that achieve neutralizing antibody quadruple growth rate or achieve the neutralizing antibody serostatus cutoffs for HPV Types 6, 11, 16 and 18 in participants 20 to 45 Years of Age at least 1 month post Dose 3.(1 month post vaccination 3 (Month 7))
- The neutralizing antibody GMTs for HPV Types 31, 33, 45 and 52 in participants 20 to 45 Years of Age at least 1 month post Dose 3.(1 month post vaccination 3 (Month 7))
- Percentage of participants that achieve neutralizing antibody quadruple growth ratefor HPV Types 31, 33, 45 and 52 in participants 20 to 45 Years of Age at least 1 month post Dose 3.(1 month post vaccination 3 (Month 7))
- Percentage of participants that achieve neutralizing antibody quadruple growth rate or achieve the neutralizing antibody serostatus cutoffs for HPV Types 31, 33, 45 and 52 in participants 20 to 45 Years of Age at least 1 month post Dose 3.(1 month post vaccination 3 (Month 7))
- Percentage of Participants Who Report at Least 1 Solicited Injection-site and Systemic Adverse Event 30 minutes post any vaccination(30 minutes post any vaccination)
- Percentage of Participants Who Report at Least 1 Solicited Adverse Event 7 days post any vaccination(7 days post any vaccination)
- Percentage of Participants Who Report at Least 1 Solicited and Unsolicited Adverse Event 30 days post any vaccination(30 days post any vaccination)
- Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE) from 1st vaccination to the completion of study(Day 1 to 6 months post vaccination 3)
- Percentage of Participants Who Experience Pregnancy from 1st vaccination to the completion of study(Day 1 to 6 months post vaccination 3)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesHPV InfectionsCIN1CIN2CIN3VaIN1VaIN2VaIN3Cervical CancerVaginal CancerGenital WartVIN 1VIN 2VIN 3Vulvar CancerAISNCT05372016Shanghai Bovax Biotechnology Co., Ltd.1,200
已完成
1 期
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCervical CancersCIN1CIN2CIN 3Invasive CarcinomaMild Dysplasia of VulvaModerate Dysplasia of VulvaVin IIIVaIN1VaIN2VaIN3Genital WartAISVulvar CancerVaginal CancerNCT03676101Shanghai Bovax Biotechnology Co., Ltd.90
进行中（未招募）
3 期
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)Papillomavirus InfectionsNCT05285826Merck Sharp & Dohme LLC8,100
进行中（未招募）
3 期
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9Genital WartCINPapillomavirus InfectionsCervical CancerVINNCT05580341Shanghai Zerun Biotechnology Co.,Ltd1,200
进行中（未招募）
3 期
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)Papillomavirus InfectionsNCT03998254Merck Sharp & Dohme LLC6,000